Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Biotech    DIM   FR0013154002

SARTORIUS STEDIM BIOTECH

(DIM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sartorius Stedim Biotech : The underlying trend is to the upside

11/09/2020 | 11:33am EST
long trade
Live
Entry price : 320.2€ | Target : 400.14€ | Stop-loss : 276€ | Potential : 24.97%
Sartorius Stedim Biotech's shares display attractive technical aspects to anticipate a comeback of the underlying trend.
Investors have an opportunity to buy the stock and target the € 400.14.
Sartorius Stedim Biotech : Sartorius Stedim Biotech : The underlying trend is to the upside
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

Strengths
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company returns high margins, thereby supporting business profitability.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 222.2 EUR

Weaknesses
  • Based on current prices, the company has particularly high valuation levels.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 94.67 times its estimated earnings per share for the ongoing year.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart
Subsector Medical Equipment, Supplies & Distribution - NEC
1st jan.Capitalization (M$)Investor Rating
SARTORIUS STEDIM BIOTECH6.46%34 549
ABBOTT LABORATORIES1.65%190 701
MEDTRONIC PLC-0.28%157 229
BECTON, DICKINSON AND COMPA..4.60%76 127
HOYA CORPORATION-2.24%50 041
ALIGN TECHNOLOGY, INC.6.15%44 726
BAXTER INTERNATIONAL INC.-0.25%40 886
DEXCOM, INC.-4.20%34 013
ZIMMER BIOMET HOLDINGS3.91%33 189
TERUMO CORPORATION-4.06%30 113
SYSMEX CORPORATION3.63%25 867
More Results

© MarketScreener.com 2020

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2020 1 877 M 2 267 M 2 267 M
Net income 2020 342 M 412 M 412 M
Net Debt 2020 261 M 315 M 315 M
P/E ratio 2020 83,3x
Yield 2020 0,30%
Capitalization 28 576 M 34 549 M 34 505 M
EV / Sales 2020 15,4x
EV / Sales 2021 12,7x
Nbr of Employees 6 979
Free-Float 25,7%
Upcoming event on SARTORIUS STEDIM BIOTECH
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 289,63 €
Last Close Price 310,00 €
Spread / Highest target 25,2%
Spread / Average Target -6,57%
Spread / Lowest Target -37,7%
EPS Revisions
Managers and Directors
NameTitle
Joachim Kreuzburg Chairman & Chief Executive Officer
Volker Niebel Executive VP-Operations & Information Technology
Oscar-Werner Reif Executive VP-Research & Development
Henri Riey Independent Non-Executive Director
Anne-Marie Graffin Independent Non-Executive Director